Skip to content
value.today

Cortexyme, Inc.

Total raised
$92 M
2 rounds on record
Latest round
$84 M
May 2018
First round on record
Dec 2015
Today
Went public
See the company page

Cortexyme, Inc. is listed today as IRulya Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Cortexyme, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2026$115 MPrivate placement after listing$50 to $250 million

Cortexyme, Inc.: Private sale, May 2026

Investors in this round

27 investors had bought by the notice of Jun 11, 2026: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cortexyme, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$115 M of $186 M offered; $72 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$7,861,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Brendan Hannah · Executive Officer
  • Brigette Roberts · Executive Officer, Director
  • Charles Ryan · Executive Officer
  • Dirk Thye · Executive Officer, Director
  • Christopher Senner · Director
  • David Lamond · Director
  • June Bray · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • LifeSci Capital (CRD 000168404) · New York, New YorkSold in all US states

Remarks in the notice

  • On the amounts: “Offering amount includes (a) gross proceeds from sale of shares of preferred stock and warrants and (b) an aggregate gross proceeds that may be received in the future upon the cash exercise in full of the warrants.”

Signed by Dirk Thye, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 11, 2026. Read the notice at the SEC.

equity, optionsSEC
Jun 2025$11 MPrivate placement after listing$10 to $50 million

Cortexyme, Inc.: Private sale, Jun 2025

Investors in this round

15 investors had bought by the notice of Jul 1, 2025: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cortexyme, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $22 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$689,299
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in California

People named in the notice

  • Brendan Hannah · Executive Officer
  • Charles Ryan · Executive Officer
  • Dirk Thye · Executive Officer, Director
  • Christopher Senner · Director
  • David Lamond · Director
  • June Bray · Director
  • Luca Benatti · Director
  • Margi McLoughlin · Director
  • Rajiv Patni · Director
  • Una Ryan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Citizens JMP Securities, LLC (CRD 22208) · New York, New YorkSold in CA, CT, FL, IL, MA, MD, NV, NY, OR, TN, TX, WA

Remarks in the notice

  • On the amounts: “Offering amount includes (a) gross proceeds from sale of shares of common stock, pre-funded warrants and common warrants and (b) an aggregate gross proceeds that may be received in the future upon the cash exercise in full of the warrants.”

Signed by Brendan Hannah, Chief Business Officer. Source: SEC Form D, newest notice filed Jul 1, 2025. Read the notice at the SEC.

equity, optionsSEC
May 2018$84 MNo. 2$50 to $250 million

Cortexyme, Inc.: Raise no. 2, May 2018

Investors in this round

36 investors had bought by the notice of May 31, 2018: 36 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cortexyme, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$84 M of $86 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Casey Lynch · Executive Officer, Director
  • Kristen Gafric · Executive Officer
  • David Lamond · Director
  • Ilan Zipkin · Director
  • Margi McLoughlin · Director
  • Roger Quy · Director
  • Stephen Dominy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Casey Lynch, Ceo. Source: SEC Form D, newest notice filed May 31, 2018. Read the notice at the SEC.

equitySEC
Dec 2015$8 MNo. 1$2 to $10 million

Cortexyme, Inc.: Raise no. 1, Dec 2015

Investors in this round

13 investors had bought by the notice of Jan 5, 2016: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Cortexyme, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $16 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Casey Lynch · Executive Officer, Director
  • Kristen Gafric · Executive Officer
  • David Lamond · Director
  • Ilan Zipkin · Director
  • Margi McLoughlin · Director
  • Stephen Dominy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Casey Lynch, Ceo. Source: SEC Form D, newest notice filed Jan 5, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Cortexyme, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).

    SEC Form D · Jun 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2026

That is all the official record says: Cortexyme, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Cortexyme, Inc. are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Cortexyme, Inc.
InvestorKindAmountRoundRoleSource
David LamondPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2019)SEC Form 3
Pfizer IncFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Pfizer Strategic Investment Holdings LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Pfizer Ventures (US) LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Takeda Pharmaceutical Co LTDCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Takeda Pharmaceuticals International AGCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Takeda Pharmaceuticals U.S.A., Inc.Companynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3
Takeda Ventures, Inc.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2019)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 36 investors.

Largest shareholders today

Institutions holding IRulya Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Cortexyme, Inc.
NameRoleNamed in
Brendan HannahExecutive officerJun 2026
Brigette RobertsExecutive officerJun 2026
Charles RyanExecutive officerJun 2026
Dirk ThyeExecutive officerJun 2026
Casey LynchExecutive officerMay 2018
Kristen GafricExecutive officerMay 2018
Brigette RobertsDirectorJun 2026
Christopher SennerDirectorJun 2026
David LamondDirectorJun 2026
Dirk ThyeDirectorJun 2026
June BrayDirectorJun 2026
Luca BenattiDirectorJul 2025
Margi McLoughlinDirectorJul 2025
Rajiv PatniDirectorJul 2025
Una RyanDirectorJul 2025
Casey LynchDirectorMay 2018
Ilan ZipkinDirectorMay 2018
Roger QuyDirectorMay 2018
Stephen DominyDirectorMay 2018

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.